Literature DB >> 29782558

Osimertinib in untreated epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer.

Vanesa Gregorc1, Chiara Lazzari1, Niki Karachaliou2, Rafael Rosell3,4, Mariacarmela Santarpia5.   

Abstract

Entities:  

Year:  2018        PMID： 29782558      PMCID： PMC5943214          DOI： 10.21037/tlcr.2018.03.19

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  24 in total

1.  Pharmacokinetics of gefitinib and erlotinib.

Authors:  Dominique Levêque
Journal:  Lancet Oncol       Date:  2011-11       Impact factor: 41.316

2.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Authors:  Rafael Rosell; Enric Carcereny; Radj Gervais; Alain Vergnenegre; Bartomeu Massuti; Enriqueta Felip; Ramon Palmero; Ramon Garcia-Gomez; Cinta Pallares; Jose Miguel Sanchez; Rut Porta; Manuel Cobo; Pilar Garrido; Flavia Longo; Teresa Moran; Amelia Insa; Filippo De Marinis; Romain Corre; Isabel Bover; Alfonso Illiano; Eric Dansin; Javier de Castro; Michele Milella; Noemi Reguart; Giuseppe Altavilla; Ulpiano Jimenez; Mariano Provencio; Miguel Angel Moreno; Josefa Terrasa; Jose Muñoz-Langa; Javier Valdivia; Dolores Isla; Manuel Domine; Olivier Molinier; Julien Mazieres; Nathalie Baize; Rosario Garcia-Campelo; Gilles Robinet; Delvys Rodriguez-Abreu; Guillermo Lopez-Vivanco; Vittorio Gebbia; Lioba Ferrera-Delgado; Pierre Bombaron; Reyes Bernabe; Alessandra Bearz; Angel Artal; Enrico Cortesi; Christian Rolfo; Maria Sanchez-Ronco; Ana Drozdowskyj; Cristina Queralt; Itziar de Aguirre; Jose Luis Ramirez; Jose Javier Sanchez; Miguel Angel Molina; Miquel Taron; Luis Paz-Ares
Journal:  Lancet Oncol       Date:  2012-01-26       Impact factor: 41.316

Review 3.  Feasibility of cell-free circulating tumor DNA testing for lung cancer.

Authors:  Mariacarmela Santarpia; Niki Karachaliou; Maria González-Cao; Giuseppe Altavilla; Elisa Giovannetti; Rafael Rosell
Journal:  Biomark Med       Date:  2016-03-14       Impact factor: 2.851

4.  Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Authors:  Lecia V Sequist; James Chih-Hsin Yang; Nobuyuki Yamamoto; Kenneth O'Byrne; Vera Hirsh; Tony Mok; Sarayut Lucien Geater; Sergey Orlov; Chun-Ming Tsai; Michael Boyer; Wu-Chou Su; Jaafar Bennouna; Terufumi Kato; Vera Gorbunova; Ki Hyeong Lee; Riyaz Shah; Dan Massey; Victoria Zazulina; Mehdi Shahidi; Martin Schuler
Journal:  J Clin Oncol       Date:  2013-07-01       Impact factor: 44.544

5.  The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial.

Authors:  Carlota Costa; Miguel Angel Molina; Ana Drozdowskyj; Ana Giménez-Capitán; Jordi Bertran-Alamillo; Niki Karachaliou; Radj Gervais; Bartomeu Massuti; Jia Wei; Teresa Moran; Margarita Majem; Enriqueta Felip; Enric Carcereny; Rosario Garcia-Campelo; Santiago Viteri; Miquel Taron; Mayumi Ono; Petros Giannikopoulos; Trever Bivona; Rafael Rosell
Journal:  Clin Cancer Res       Date:  2014-02-03       Impact factor: 12.531

6.  CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials.

Authors:  G Goss; C-M Tsai; F A Shepherd; M-J Ahn; L Bazhenova; L Crinò; F de Marinis; E Felip; A Morabito; R Hodge; M Cantarini; M Johnson; T Mitsudomi; P A Jänne; J C-H Yang
Journal:  Ann Oncol       Date:  2018-03-01       Impact factor: 32.976

7.  Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer.

Authors:  Geoffrey R Oxnard; Kenneth S Thress; Ryan S Alden; Rachael Lawrance; Cloud P Paweletz; Mireille Cantarini; James Chih-Hsin Yang; J Carl Barrett; Pasi A Jänne
Journal:  J Clin Oncol       Date:  2016-06-27       Impact factor: 44.544

8.  Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance.

Authors:  D Zheng; X Ye; M Z Zhang; Y Sun; J Y Wang; J Ni; H P Zhang; L Zhang; J Luo; J Zhang; L Tang; B Su; G Chen; G Zhu; Y Gu; J F Xu
Journal:  Sci Rep       Date:  2016-02-12       Impact factor: 4.379

9.  Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

Authors:  Jean-Charles Soria; Yuichiro Ohe; Johan Vansteenkiste; Thanyanan Reungwetwattana; Busyamas Chewaskulyong; Ki Hyeong Lee; Arunee Dechaphunkul; Fumio Imamura; Naoyuki Nogami; Takayasu Kurata; Isamu Okamoto; Caicun Zhou; Byoung Chul Cho; Ying Cheng; Eun Kyung Cho; Pei Jye Voon; David Planchard; Wu-Chou Su; Jhanelle E Gray; Siow-Ming Lee; Rachel Hodge; Marcelo Marotti; Yuri Rukazenkov; Suresh S Ramalingam
Journal:  N Engl J Med       Date:  2017-11-18       Impact factor: 91.245

10.  AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.

Authors:  Darren A E Cross; Susan E Ashton; Serban Ghiorghiu; Cath Eberlein; Caroline A Nebhan; Paula J Spitzler; Jonathon P Orme; M Raymond V Finlay; Richard A Ward; Martine J Mellor; Gareth Hughes; Amar Rahi; Vivien N Jacobs; Monica Red Brewer; Eiki Ichihara; Jing Sun; Hailing Jin; Peter Ballard; Katherine Al-Kadhimi; Rachel Rowlinson; Teresa Klinowska; Graham H P Richmond; Mireille Cantarini; Dong-Wan Kim; Malcolm R Ranson; William Pao
Journal:  Cancer Discov       Date:  2014-06-03       Impact factor: 39.397
View more
  6 in total

1.  Co-occurring genetic alterations and primary EGFR T790M mutations detected by NGS in pre-TKI-treated NSCLCs.

Authors:  Yuan Tang; Nanying Che; Yang Yu; Yun Gao; Huaiyin Shi; Qin Feng; Bing Wei; Liheng Ma; Min Gao; Jie Ma; Dongmei Lin
Journal:  J Cancer Res Clin Oncol       Date:  2019-11-06       Impact factor: 4.553

2.  Targeting S100A9-ALDH1A1-Retinoic Acid Signaling to Suppress Brain Relapse in EGFR-Mutant Lung Cancer.

Authors:  Seoyoung Han; Yifan Tai; Wanchao Ma; Courtney Coker; Anup Kumar Biswas; S Aidan Quinn; Ahmad Rushdi Shakri; Timothy James Zhong; Hanna Scholze; Galina G Lagos; Angeliki Mela; Katia Manova-Todorova; Elisa de Stanchina; Adolfo A Ferrando; Cathy Mendelsohn; Peter Canoll; Helena A Yu; Paul K Paik; Anjali Saqi; Catherine A Shu; Mark G Kris; Joan Massague; Swarnali Acharyya
Journal:  Cancer Discov       Date:  2022-04-01       Impact factor: 38.272

3.  Combination therapy of brain radiotherapy and EGFR-TKIs is more effective than TKIs alone for EGFR-mutant lung adenocarcinoma patients with asymptomatic brain metastasis.

Authors:  Yanxin Chen; Jianping Wei; Jing Cai; Anwen Liu
Journal:  BMC Cancer       Date:  2019-08-09       Impact factor: 4.430

4.  Complete response of radioresistant brain metastases from non-small cell lung cancer with temozolomide: A case report and literature review.

Authors:  Yi Yang; Yu Pu; Nan Dai; Dong Wang; Mingfang Xu
Journal:  Medicine (Baltimore)       Date:  2020-12-18       Impact factor: 1.817

5.  Exploration of the Tumor-Suppressive Immune Microenvironment by Integrated Analysis in EGFR-Mutant Lung Adenocarcinoma.

Authors:  Teng Li; Xiaocong Pang; Junyun Wang; Shouzheng Wang; Yiying Guo; Ning He; Puyuan Xing; Junling Li
Journal:  Front Oncol       Date:  2021-05-31       Impact factor: 6.244

6.  A multicenter real-world study of tumor-derived DNA from pleural effusion supernatant in genomic profiling of advanced lung cancer.

Authors:  Shidai Jin; Chengzhi Zhou; Xue Hou; Zaiwen Fan; Jun Zhao; Xinghao Ai; Yuxing Chu; Rongrong Chen; Renhua Guo; Likun Chen
Journal:  Transl Lung Cancer Res       Date:  2020-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.